<DOC>
	<DOCNO>NCT01001364</DOCNO>
	<brief_summary>This study primary objective compare impact two product contain budesonide formoterol individual capsule inhalation powder pulmonary function subject persistent asthma .</brief_summary>
	<brief_title>A Comparative Study Between Foraseq And Formoterol/Budesonide Inhalation Capsules Patients With Asthma</brief_title>
	<detailed_description>This study primary objective compare impact two product contain budesonide formoterol individual capsule inhalation powder pulmonary function subject persistent asthma . This non-inferiority study , hypothesis difference pulmonary function measure group study end . Therefore , study primary endpoint force expiratory volume 1 second ( FEV1 ) final visit ( FV ) study arm . This study secondary objective compare impact clinical control two product contain budesonide formoterol individual capsule inhalation powder subject persistent asthma . The secondary endpoint consider study : - Score asthma control questionnaire ( ACQ-7 ) 34 end study ; - Peak expiratory flow ( PEF ) throughout study ; - Symptoms score end study ; - FEV1 throughout study ; - Treatment safety , include serum cortisol dosage ; - Frequency observe adverse event . Some eligibility criterion : - Current use inhaled corticosteroid ( equivalent beclometasone dipropionate 1000µg ) associate long-acting β2-adrenergics relief medication ( salbutamol equivalent ) ; - Diagnosis mild moderate persistent asthma , per ARIA classification , 35 symptom least 6 month , clinically stable least 1 month ACQ-7 test34 ( see Attachment D ) &lt; 3.0 ;</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Sign ICF ( see Attachment A ) ; Age ≥12 year old Diagnosis mild moderate persistent asthma , per ARIA classification , 35 symptom least 6 month , clinically stable least 1 month ACQ7 test34 ( see Attachment D ) &lt; 3.0 ; Current use inhale corticosteroid ( equivalent beclometasone dipropionate 1000µg ) associate longacting β2adrenergics relief medication ( salbutamol equivalent ) ; Initial FEV1 least 50 % normal value estimate . Serum cortisol evaluation within normal value Use oral parenteral corticosteroid within last 3 month ; Need hospitalization due asthma within last 3 month ; Active tabagism , define use cigarette , pipe , cigar type amount within last 3 month ; Severe comorbidity , cardiovascular , renal , liver , neurologic , neoplastic , blood , infectious , dermatologic , neurologic , psychiatric chronic respiratory disease , asthma ; Recent participation ( &lt; 6 month ) plan participation , study , clinical trial involve drug nature study type intervention asthma treatment ; Intolerance allergy compound drug evaluate study ; Pregnancy lactation ; Chronic use routine oral intravenous βblocker drug , even ophthalmic solution .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>